We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
-2.21%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$704M
AUM Growth
-$99.5M
Cap. Flow
-$67.1M
Cap. Flow %
-9.54%
Top 10 Hldgs %
90.93%
Holding
52
New
12
Increased
3
Reduced
15
Closed
20

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.5M
2
CCRN
Cross Country Healthcare
CCRN
+$1.72M
3
CFRX
ContraFect Corporation
CFRX
+$904K
4
FORA
Forian
FORA
+$188K

Top Sells

Rank Stock Value
1
VIR icon
Vir Biotechnology
VIR
+$12.6M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$10.8M
3
YMAB
Y-mAbs Therapeutics
YMAB
+$9.01M
4
GH icon
Guardant Health
GH
+$8.75M
5
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$7.84M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Miscellaneous 3.25%
3 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$286M 40.64%
2,075,402
-48,653
-2% -$6.19M
QDEL icon
2
QuidelOrtho
QDEL
$808M
$115M 16.4%
855,068
-51,587
-6% -$7.18M
OPK icon
3
Opko Health
OPK
$1.17B
$58.8M 8.35%
12,219,073
-600,000
-5% -$2.43M
VIR icon
4
Vir Biotechnology
VIR
$1.8B
$36M 5.12%
861,008
-320,349
-27% -$12.6M
AGEN
5
Agenus
AGEN
$312M
$29.3M 4.17%
463,957
-16,875
-4% -$1.33M
PACB icon
6
Pacific Biosciences
PACB
$404M
$29.1M 4.14%
1,420,652
-24,307
-2% -$587K
PFE icon
7
Pfizer
PFE
$158B
$28M 3.99%
+475,000
New +$23.5M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.07B
$23.1M 3.29%
1,670,733
-250,000
-13% -$3.31M
AXDX
9
DELISTED
Accelerate Diagnostics
AXDX
$18.9M 2.69%
362,755
-12,357
-3% -$688K
PFE icon
10
PUT
Pfizer
PFE
$158B
$15M 2.14%
+1,400,000
New +$69.4M
FORA
11
DELISTED
Forian
FORA
$11M 1.56%
1,219,661
+19,701
+2% +$188K
AWH
12
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$9.82M 1.4%
369,806
-206,667
-36% -$7.84M
DMTK
13
DELISTED
DermTech, Inc. Common Stock
DMTK
$9.53M 1.35%
602,907
-9,400
-2% -$226K
CDAK
14
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$7.34M 1.04%
659,191
-40,809
-6% -$566K
ATRS
15
DELISTED
Antares Pharma, Inc.
ATRS
$6.14M 0.87%
1,720,000
-180,000
-9% -$630K
CFRX
16
DELISTED
ContraFect Corporation
CFRX
$5.13M 0.73%
24,405
+3,294
+16% +$904K
IMMP
17
Immutep
IMMP
$55M
$3.2M 0.46%
976,156
-23,844
-2% -$91K
CCRN
18
DELISTED
Cross Country Healthcare
CCRN
$1.97M 0.28%
+71,000
New +$1.72M
VIR icon
19
PUT
Vir Biotechnology
VIR
$1.8B
$1.58M 0.22%
+287,600
New +$11.3M
BCRX icon
20
PUT
BioCryst Pharmaceuticals
BCRX
$2.07B
$1.38M 0.2%
+700,000
New +$9.26M
SPY icon
21
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$808B
$1.31M 0.19%
500,000
+250,000
+100% +$115M
ARKG icon
22
PUT
ARK Genomic Revolution ETF
ARKG
$1.95B
$1.08M 0.15%
+350,000
New +$24.2M
SLNO
23
DELISTED
Soleno Therapeutics
SLNO
$874K 0.12%
142,133
– –
OPK icon
24
PUT
Opko Health
OPK
$1.17B
$685K 0.1%
+757,300
New +$3.06M
XBIT icon
25
PUT
XBiotech
XBIT
$66.8M
$674K 0.1%
+500,000
New +$6.51M
1
2 3

Similar funds

EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM
CWA
Clearview Wealth Advisors Salem, Oregon $158M AUM 14.25% 1-Year Est. Return
CNFG
Creegan & Nassoura Financial Group Portsmouth, New Hampshire $154M AUM 17.18% 1-Year Est. Return
VA
Verus Advisory Seattle, Washington $153M AUM
PSB
Passumpsic Savings Bank St. Johnsbury, Vermont $183M AUM

Oracle Investment Management's Q4 2021 Portfolio in Review

As of Q4 2021, Oracle Investment Management held 52 positions worth $704M, down 12% from $803M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Oracle Investment Management withdrew a net $67.1M in Q4 2021, closing 20 positions and reducing 15 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $10.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Energy.

Against the trend, Oracle Investment Management opened a new position in Pfizer worth $28M.

  • Oracle Investment Management's largest Q4 2021 buy was Pfizer: 475,000 shares worth $28M.
  • Oracle Investment Management added most to ContraFect Corporation in Q4 2021, an estimated $904K increase.
  • Oracle Investment Management's biggest Q4 2021 reduction was Vir Biotechnology, cutting an estimated $12.6M.
  • Oracle Investment Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $10.8M.
  • Oracle Investment Management's ten largest holdings make up 91% of its $704M portfolio in Q4 2021.
  • Oracle Investment Management opened 12 new positions and closed 20 in Q4 2021.
  • Oracle Investment Management's portfolio value fell 12% quarter-over-quarter to $704M.

Based on Oracle Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.